Quantum量子訊息有限公司

神經學生物標記市場Neurology Biomarkers Market

完整報告名稱與涵蓋範圍
Neurology Biomarkers Market: Size, Share and Forecast 2025-2035

報告摘要

The Neurology Biomarkers Market encompasses the research, development, and commercialization of biological indicators used to detect, diagnose, monitor, and predict neurological diseases and therapeutic responses. This market includes molecular, imaging, physiological, and genetic biomarkers applied across conditions such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Key purchasers include pharmaceutical and biotechnology companies, diagnostic laboratories, and academic research institutions, all seeking to advance drug discovery, facilitate clinical trials, and enable personalized medicine approaches in neurological care.

The market is estimated at $2.4 Bn in 2025 and is forecast to reach $8.2 Bn in 2035, growing at a CAGR of 13.1% from 2025 to 2035. Demand is driven by the rising prevalence of neurological diseases and increased R&D funding for neurological therapies, alongside technological advancements in biomarker identification. However, high development and validation costs, coupled with a lack of standardization, present restraints to market expansion.

The market is segmented by Type (e.g., Amyloid Beta, Tau Protein), Technology (e.g., Immunoassays, Mass Spectrometry), Application (e.g., Alzheimer's Disease, Parkinson's Disease), End-User (e.g., Pharmaceutical & Biotechnology Companies, Diagnostic Laboratories), Source (e.g., Cerebrospinal Fluid, Blood), and Product & Service (e.g., Assay Kits, Analyzers & Instruments). Key regions include North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Leading companies include Quanterix, C2N Diagnostics, and Denali Therapeutics. The full report provides detailed analysis across these segments and regions.

Market-Reports.com estimates the Neurology Biomarkers market at $2.4 Bn in 2025 and forecasts $8.2 Bn by 2035, a compound annual growth rate (CAGR) of 13.1%. The forecast is given in conservative, base and optimistic scenarios.

The report segments the market by type (Amyloid Beta Biomarkers, Tau Protein Biomarkers, Alpha-Synuclein Biomarkers, Neurofilament Light Chain Biomarkers, Cerebrospinal Fluid Biomarkers, Blood Biomarkers, Genetic Biomarkers, Inflammatory Biomarkers); technology (Immunoassays, Mass Spectrometry, Chromatography, Next-Generation Sequencing, Polymerase Chain Reaction, Flow Cytometry, In Situ Hybridization); application (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Huntington's Disease, Amyotrophic Lateral Sclerosis, Traumatic Brain Injury, Stroke, Neuro-Oncology); end-user (Pharmaceutical & Biotechnology Companies, Diagnostic Laboratories, Academic & Research Institutions, Hospitals & Clinics, Contract Research Organizations); source (Cerebrospinal Fluid, Blood, Urine, Saliva, Tissue Biopsy, Hair Follicles); product & service (Assay Kits, Reagents & Consumables, Analyzers & Instruments, Software & Bioinformatics Tools, Biomarker Discovery Services, Contract Research Services), with market size and growth for every segment from 2025 to 2035.

Regional coverage: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, with forecasts for 26 countries.

Companies profiled include Quanterix, C2N Diagnostics, Denali Therapeutics, Alector, Prothena, Acumen Pharmaceuticals, Voyager Therapeutics, Neurocrine Biosciences, Amprion, Centogene.

授權報價

Single User$4,750 USD
Multi User$5,750 USD
Enterprise / Global Site Licence$6,750 USD

目錄 Table of Contents

Chapter 1. Research Overview 1.1 Market Definition 1.1.1 Research Objectives 1.1.2 Market Definition & Industry Standards 1.1.3 Scope and Limitations 1.2 Scope of Study 1.2.1 Geographical Scope 1.2.2 Segmental Scope 1.2.3 Company Scope 1.3 Research Architecture 1.3.1 Research Design 1.3.2 Research Phases 1.4 Research Methodology 1.4.1 Research Framework 1.4.2 Market Size Estimation Approach 1.4.3 Data Triangulation and Validation Chapter 2. Executive Summary 2.1 Market Snapshot 2.1.1 Market Summary 2.1.2 Key Highlights by Segments 2.1.3 Key Highlights by Region 2.1.4 Key Highlights by Company 2.2 Future Outlook 2.2.1 Market Projections 2.2.2 Emerging Trends 2.3 Strategic Recommendations 2.3.1 Key Findings & Takeaways 2.3.2 Critical Success Factors 2.3.3 Emerging Segmental Opportunities 2.3.4 Regional Growth Projections Chapter 3. Market Dynamics 3.1 TDRO 3.1.1 Market Trends 3.1.2 Market Drivers 3.1.3 Market Restraints 3.1.4 Market Opportunities 3.1.5 Market Forces Priority Matrix 3.2 Impact Analysis 3.2.1 Impact of Emerging Technologies 3.2.2 Impact of AI & Automation 3.2.3 Impact of Sustainability Mandates 3.2.4 Multi-Factor Industry Impact Matrix 3.3 Macroeconomic Analysis 3.3.1 Global GDP Outlook & Implications 3.3.2 Inflation, Interest Rates & Capital Cost 3.3.3 Foreign Exchange Dynamics 3.3.4 Global Trade Volume Trends 3.3.5 Macro Sensitivity Dashboard 3.4 Geopolitical Analysis 3.4.1 Critical Trade Dependencies 3.4.2 Tariffs & Sanctions Regime 3.4.3 Regional Conflicts and Trade Chokepoints 3.4.4 Geopolitical Risk Index by Region 3.5 Parent Market Analysis 3.5.1 Global Parent Market Size & Growth 3.5.2 Parent Market Segmentation 3.5.3 Target Market as a Share of Parent Market 3.5.4 Adjacent & Substitute Market Overview 3.6 Value Chain Analysis 3.6.1 Value Chain Architecture 3.6.2 Raw Material & Input Suppliers 3.6.3 Manufacturing & Production Layer 3.6.4 Technology & Platform Development 3.6.5 Distribution & Channel Layer 3.6.6 End-User Delivery & Service 3.6.7 Value Distribution Across the Chain 3.7 Regulatory Framework 3.7.1 Product & Safety Regulations 3.7.2 Patent & Clinical Validation Requirements 3.7.3 Reimbursement & Pricing Policies 3.7.4 Data Privacy Laws 3.7.5 Government Funding, Incentives & Trade Policies Chapter 4. Market Strategy 4.1 Strategic Recommendations 4.1.1 Short-Term (0-12 months) 4.1.2 Medium-Term (1-3 years) 4.1.3 Long-Term (3-5+ years) 4.2 Go-To-Market Strategy 4.2.1 Market Entry Approaches 4.2.2 Partnership Models 4.3 Risk and Mitigation Strategy 4.3.1 Operational Risks 4.3.2 Technological Risks 4.3.3 Regulatory & Compliance Risks 4.3.4 Data Privacy & Security Risks 4.4 Demand-Supply Gap Analysis 4.4.1 Current Gap Assessment 4.4.2 Future Projections 4.5 Trade & Logistics Constraints 4.5.1 Cross-border Data Transfer 4.5.2 Technology Import-Export Regulations 4.6 Price-Cost-Margin Trends 4.6.1 Pricing Models 4.6.2 Cost Structure Analysis 4.6.3 Margin Trends by Region 4.7 Market Penetration 4.7.1 Existing Market Share 4.7.2 Growth Opportunities 4.8 Consumer Analysis 4.8.1 Consumer Buying Interest 4.8.2 Case Study Analysis 4.8.3 Switching Costs and Loyalty Drivers 4.9 Strategic Frameworks 4.9.1 Porter's Five Forces Analysis 4.9.2 PESTLE Analysis 4.9.3 4Ps Model 4.9.4 ANSOFF Matrix Chapter 5. Market Size Estimation Methodology 5.1 Estimation Framework 5.1.1 Base / Optimistic / Conservative Scenarios - Definition 5.1.2 Forecast Assumptions and Limitations 5.2 Top-Down Approach 5.2.1 Parent Market Derivation 5.2.2 Allocation Ratios 5.3 Bottom-Up Approach 5.3.1 Demand-Side Modeling (Consumption-Based) 5.3.2 Supply-Side Modeling (Production-Based) 5.3.3 Company Revenue Aggregation 5.3.4 Consumption Intensity Model 5.4 Market Sizing Reconciliation & Triangulation 5.4.1 Multi-Method Triangulation 5.4.2 Weighted Average Reconciliation 5.4.3 Internal Consistency Validation 5.5 Forecasting Methodology 5.5.1 CAGR Factor Decomposition 5.5.2 Scenario Analysis (Conservative / Base / Optimistic) 5.5.3 Year-by-Year Compound Growth Forecasting 5.6 Segmentation & Regional Breakdown 5.6.1 Segment Breakdown Allocation 5.6.2 Regional Distribution Modelling 5.6.3 Country-Level Breakdown 5.7 Data Validation & Final Review 5.7.1 Consistency Checks 5.7.2 Final Data Triangulation Chapter 6. Market Size Overview 6.1 Total Addressable Market (TAM) 6.2 Serviceable Addressable Market (SAM) 6.3 Market Size by Volume (Units / Subscriptions / Users) 6.4 CAGR Analysis 6.4.1 By Segment 6.4.2 By Region 6.5 Scenario Analysis 6.5.1 Optimistic 6.5.2 Conservative 6.5.3 Base 6.6 Forecast Analysis Chapter 7. Market Size by Segments By Type Amyloid Beta Biomarkers Tau Protein Biomarkers Alpha-Synuclein Biomarkers Neurofilament Light Chain Biomarkers Cerebrospinal Fluid Biomarkers Blood Biomarkers Genetic Biomarkers Inflammatory Biomarkers By Technology Immunoassays Mass Spectrometry Chromatography Next-Generation Sequencing Polymerase Chain Reaction Flow Cytometry In Situ Hybridization By Application Alzheimer's Disease Parkinson's Disease Multiple Sclerosis Huntington's Disease Amyotrophic Lateral Sclerosis Traumatic Brain Injury Stroke Neuro-oncology By End-User Pharmaceutical & Biotechnology Companies Diagnostic Laboratories Academic & Research Institutions Hospitals & Clinics Contract Research Organizations By Source Cerebrospinal Fluid Blood Urine Saliva Tissue Biopsy Hair Follicles By Product & Service Assay Kits Reagents & Consumables Analyzers & Instruments Software & Bioinformatics Tools Biomarker Discovery Services Contract Research Services Chapter 8. Market Size by Region Asia Pacific China Japan India South Korea Australia Taiwan Singapore Malaysia Rest of Asia Pacific North America United States Canada Mexico Europe Germany United Kingdom France Italy Spain Russia Rest of Europe South America Brazil Argentina Rest of South America Middle East & Africa Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Emerging Areas 8.6 Local Market Review North America Europe Asia-Pacific Latin America Middle East & Africa 8.7 Local Competition Review North America Europe Asia-Pacific Latin America Middle East & Africa Chapter 9. Market Intelligence 9.1 Recent Developments 9.1.1 New Product Developments 9.1.2 Product Launches 9.1.3 Business Expansions 9.1.4 Partnerships, JVs, and Collaborations 9.1.5 Mergers and Acquisitions 9.1.6 Regulatory Approvals and Certifications Chapter 10. Competition Analysis 10.1 Competition Analysis Overview 10.2 Market Positioning 10.2.1 Key Player Positioning 10.2.2 Competitive Leadership Mapping 10.2.3 Star Players 10.2.4 Innovators 10.2.5 Emerging Players 10.3 Market Share 10.3.1 Global Market Share Analysis 10.3.2 Regional Market Share 10.4 Competition Benchmarking 10.4.1 Vendor Benchmarking 10.4.2 Developmental Strategy Benchmarking 10.5 Top Company Strategies 10.5.1 Strategy Overview by Key Players 10.5.2 Strategic Initiatives 10.6 Company Performance Matrix 10.6.1 Financial Performance 10.6.2 Product Portfolio Strength 10.6.3 Geographic Reach 10.7 Company Intelligence 10.7.1 Recent Strategic Moves 10.7.2 Competitive Threats Chapter 11. Company Profiles Company Profiles Quanterix C2N Diagnostics Denali Therapeutics Alector Prothena Acumen Pharmaceuticals Voyager Therapeutics Neurocrine Biosciences Amprion Centogene SomaLogic Recursion Pharmaceuticals Invitae Proteome Sciences Imeka Vaxxinity Cerecin NeuroSense Therapeutics Anavex Life Sciences Cognito Therapeutics Chapter 12. Appendix 12.1 List of Abbreviations 12.2 Glossary of Terms 12.3 Research Data Sources 12.4 Exchange Rates and Unit Conversion Tables 12.5 Disclaimer & Terms of Use 12.6 Our Clients 12.7 About Us

圖表清單 List of Tables & Figures

Table 1. Neurology Biomarkers Market estimates and forecasts, 2025-2035 (USD Billion) Table 2. Neurology Biomarkers Market: conservative, base and optimistic scenarios, 2025-2035 (USD Billion) Table 3. Neurology Biomarkers Market estimates and forecasts, by type, 2025-2035 (USD Billion) Table 4. Neurology Biomarkers Market estimates and forecasts, by technology, 2025-2035 (USD Billion) Table 5. Neurology Biomarkers Market estimates and forecasts, by application, 2025-2035 (USD Billion) Table 6. Neurology Biomarkers Market estimates and forecasts, by end-user, 2025-2035 (USD Billion) Table 7. Neurology Biomarkers Market estimates and forecasts, by source, 2025-2035 (USD Billion) Table 8. Neurology Biomarkers Market estimates and forecasts, by product & service, 2025-2035 (USD Billion) Table 9. Neurology Biomarkers Market estimates and forecasts, by region, 2025-2035 (USD Billion) Table 10. North America Neurology Biomarkers market estimates and forecasts, by type, 2025-2035 (USD Billion) Table 11. North America Neurology Biomarkers market estimates and forecasts, by technology, 2025-2035 (USD Billion) Table 12. North America Neurology Biomarkers market estimates and forecasts, by application, 2025-2035 (USD Billion) Table 13. North America Neurology Biomarkers market estimates and forecasts, by end-user, 2025-2035 (USD Billion) Table 14. North America Neurology Biomarkers market estimates and forecasts, by source, 2025-2035 (USD Billion) Table 15. North America Neurology Biomarkers market estimates and forecasts, by product & service, 2025-2035 (USD Billion) Table 16. North America Neurology Biomarkers market estimates and forecasts, by country, 2025-2035 (USD Billion) Table 17. Europe Neurology Biomarkers market estimates and forecasts, by type, 2025-2035 (USD Billion) Table 18. Europe Neurology Biomarkers market estimates and forecasts, by technology, 2025-2035 (USD Billion) Table 19. Europe Neurology Biomarkers market estimates and forecasts, by application, 2025-2035 (USD Billion) Table 20. Europe Neurology Biomarkers market estimates and forecasts, by end-user, 2025-2035 (USD Billion) Table 21. Europe Neurology Biomarkers market estimates and forecasts, by source, 2025-2035 (USD Billion) Table 22. Europe Neurology Biomarkers market estimates and forecasts, by product & service, 2025-2035 (USD Billion) Table 23. Europe Neurology Biomarkers market estimates and forecasts, by country, 2025-2035 (USD Billion) Table 24. Asia Pacific Neurology Biomarkers market estimates and forecasts, by type, 2025-2035 (USD Billion) Table 25. Asia Pacific Neurology Biomarkers market estimates and forecasts, by technology, 2025-2035 (USD Billion) Table 26. Asia Pacific Neurology Biomarkers market estimates and forecasts, by application, 2025-2035 (USD Billion) Table 27. Asia Pacific Neurology Biomarkers market estimates and forecasts, by end-user, 2025-2035 (USD Billion) Table 28. Asia Pacific Neurology Biomarkers market estimates and forecasts, by source, 2025-2035 (USD Billion) Table 29. Asia Pacific Neurology Biomarkers market estimates and forecasts, by product & service, 2025-2035 (USD Billion) Table 30. Asia Pacific Neurology Biomarkers market estimates and forecasts, by country, 2025-2035 (USD Billion) Table 31. Latin America Neurology Biomarkers market estimates and forecasts, by type, 2025-2035 (USD Billion) Table 32. Latin America Neurology Biomarkers market estimates and forecasts, by technology, 2025-2035 (USD Billion) Table 33. Latin America Neurology Biomarkers market estimates and forecasts, by application, 2025-2035 (USD Billion) Table 34. Latin America Neurology Biomarkers market estimates and forecasts, by end-user, 2025-2035 (USD Billion) Table 35. Latin America Neurology Biomarkers market estimates and forecasts, by source, 2025-2035 (USD Billion) Table 36. Latin America Neurology Biomarkers market estimates and forecasts, by product & service, 2025-2035 (USD Billion) Table 37. Latin America Neurology Biomarkers market estimates and forecasts, by country, 2025-2035 (USD Billion) Table 38. Middle East & Africa Neurology Biomarkers market estimates and forecasts, by type, 2025-2035 (USD Billion) Table 39. Middle East & Africa Neurology Biomarkers market estimates and forecasts, by technology, 2025-2035 (USD Billion) Table 40. Middle East & Africa Neurology Biomarkers market estimates and forecasts, by application, 2025-2035 (USD Billion) Table 41. Middle East & Africa Neurology Biomarkers market estimates and forecasts, by end-user, 2025-2035 (USD Billion) Table 42. Middle East & Africa Neurology Biomarkers market estimates and forecasts, by source, 2025-2035 (USD Billion) Table 43. Middle East & Africa Neurology Biomarkers market estimates and forecasts, by product & service, 2025-2035 (USD Billion) Table 44. Middle East & Africa Neurology Biomarkers market estimates and forecasts, by country, 2025-2035 (USD Billion) Table 45. Company profiles: 20 companies Fig. 1 Market segmentation Fig. 2 Neurology Biomarkers Market size and forecast, 2025-2035 (USD Billion) Fig. 3 Market growth scenarios, 2025-2035 Fig. 4 Market dynamics: drivers, restraints and opportunities Fig. 5 Neurology Biomarkers Market, by type: share, 2025 and 2035 Fig. 6 Neurology Biomarkers Market, by technology: share, 2025 and 2035 Fig. 7 Neurology Biomarkers Market, by application: share, 2025 and 2035 Fig. 8 Neurology Biomarkers Market, by end-user: share, 2025 and 2035 Fig. 9 Neurology Biomarkers Market, by source: share, 2025 and 2035 Fig. 10 Neurology Biomarkers Market, by product & service: share, 2025 and 2035 Fig. 11 Neurology Biomarkers Market, by region: share, 2025 and 2035 Fig. 12 North America Neurology Biomarkers market, by country: share, 2025 Fig. 13 Europe Neurology Biomarkers market, by country: share, 2025 Fig. 14 Asia Pacific Neurology Biomarkers market, by country: share, 2025 Fig. 15 Latin America Neurology Biomarkers market, by country: share, 2025 Fig. 16 Middle East & Africa Neurology Biomarkers market, by country: share, 2025 Fig. 17 Competitive landscape

提及公司

QuanterixC2N DiagnosticsDenali TherapeuticsAlectorProthenaAcumen PharmaceuticalsVoyager TherapeuticsNeurocrine BiosciencesAmprionCentogeneSomaLogicRecursion PharmaceuticalsInvitaeProteome SciencesImekaVaxxinityCerecinNeuroSense TherapeuticsAnavex Life SciencesCognito Therapeutics

常見問題

這份報告可以先索取樣本嗎?

可以。建議購買前先申請樣本,提出申請後約 2 個工作天內提供,您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算?

報告以美元標價,台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本(單人/多人/企業全站)價格不同,量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付?如何付款?

一般 3–7 個工作天交付,實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票,30 天內電匯付款即可。

量子訊息有限公司為 Market-Reports.com 在台灣的授權代理,提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們